Long-Term Comparison of Everolimus-Eluting and Biolimus-Eluting Stents in All-Comer Patients
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Coronary Artery Disease
- Sponsor
- University of Freiburg
- Enrollment
- 814
- Locations
- 1
- Primary Endpoint
- Composite of Death, Myocardial Infarction and Target Vessel Revascularization
- Status
- Completed
- Last Updated
- 10 years ago
Overview
Brief Summary
This study sought to investigate safety and efficacy of biolimus-eluting stents (BES) with biodegradable polymer as compared with everolimus-eluting stents (EES) with durable polymer through 3 years of follow-up.
Detailed Description
A group of 814 consecutive patients undergoing percutaneous coronary intervention (PCI) was enrolled between 2007 and 2010, of which 527 were treated with EES and 287 with BES implantation. Clinical outcome was compared in 200 pairs using propensity score matching. The primary endpoint was a composite of death, myocardial infarction (MI) and target vessel revascularisation (TVR) at two-year follow-up.
Investigators
Stéphane Cook, Prof
Principal Investigator
University of Freiburg
Eligibility Criteria
Inclusion Criteria
- •all patients with at least one BES or EES for de novo stenosis
Exclusion Criteria
- •patients with at least one non-study stent
- •patients with both study stent
- •patients with life expectancy \< 3 years
Outcomes
Primary Outcomes
Composite of Death, Myocardial Infarction and Target Vessel Revascularization
Time Frame: up to 24 months
The primary outcome is the above mentioned composite of adverse events in order to measure their cumulative incidence (i.e. the rate of occurrence of such events in the study population over a predefined time periode).
Secondary Outcomes
- Cardiovascular death(up to 24 months)
- Any Revascularization(up to 24 months)